A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs PF 06826647 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 09 Apr 2018 Planned End Date changed from 3 Nov 2018 to 30 Oct 2018.
- 09 Apr 2018 Planned primary completion date changed from 3 Nov 2018 to 30 Oct 2018.
- 02 Feb 2018 Planned End Date changed from 25 Aug 2018 to 3 Nov 2018.